Ascend Advanced Therapies, an end-to-end gene therapy development partner, has announced the addition of industry veteran Scott Law as Chief Operations Officer (COO).
He joins with the goal of streamlining operational excellence as Ascend evolves.
Scott brings more than 30 years of global pharmaceutical experience, including senior manufacturing roles at companies such as Telix Pharmaceuticals, Baxter, Emergent BioSolutions, Ferndale Laboratories and Pfizer.
Most recently, he was Senior Vice President of Global Manufacturing and Operations at Telix Pharmaceuticals, where he was responsible for the development, manufacture and commercialisation of radiopharmaceutical products.
“This is another step in the development of our organisation to bring an offering to the market that supports clients from early development all the way through to commercial production,” Mike Stella, CEO at Ascend said. “The addition of Scott further elevates our depth of talent in this market, which is a key differentiator and mainstay of the foundation at Ascend.”
The Ascend network is designed to support gene therapy customers at all stages of development across serotypes. Early-stage R&D is carried out at the San Francisco Bay Area site, with process development, optimization and forthcoming GMP QC release capabilities at the Munich, Germany site and now the GMP facility in Alachua Florida.
